Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate
- 17 June 2004
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 18 (8), 1352-1356
- https://doi.org/10.1038/sj.leu.2403416
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategiesLeukemia, 2003
- Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinibBlood, 2003
- Imatinib mesylate in combination with other chemotherapeutic drugs: In vitro studiesSeminars in Hematology, 2003
- Cytogenetic and molecular mechanisms of resistance to imatinibSeminars in Hematology, 2003
- BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571Blood, 2003
- Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemiaBlood, 2003
- Chronic Myeloid LeukemiaHematology, 2003
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective HckPublished by Elsevier BV ,2000